The Fly

Novartis upgraded to Buy from Hold at Stifel

Stifel analyst Eric Le Berrigaud upgraded Novartis to Buy from Hold with a price target of CHF 97, up from CHF 89. The analyst says his "icrementally positive stance" on Pluvicto for advanced prostate cancer and Kisqali for breast cancer more than offsets his more conservative view towards cholesterol drug Leqvio. Le Berrigaud expects a "reversal of investor sentiment towards Novartis."

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on NVS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More